PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.

Abstract The purpose of this trial was to evaluate the feasibility and efficacy of alternating platinum-based doublet chemotherapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR-mutant non-small cell lung cancer (NSCLC).
PMID
Related Publications

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.

EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.

Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.

Authors

Mayor MeshTerms
Keywords

Alternating chemotherapy

epidermal growth factor receptor tyrosine kinase inhibitor

non-small cell lung cancer

pemetrexed

Journal Title anticancer research
Publication Year Start




PMID- 29599365
OWN - NLM
STAT- MEDLINE
DCOM- 20180412
LR  - 20180412
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 4
DP  - 2018 Apr
TI  - Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for
      Patients with Non-small Cell Lung Cancer.
PG  - 2385-2390
AB  - BACKGROUND/AIM: The purpose of this trial was to evaluate the feasibility and
      efficacy of alternating platinum-based doublet chemotherapy with epidermal growth
      factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with
      EGFR-mutant non-small cell lung cancer (NSCLC). PATIENTS AND METHODS:
      Chemotherapy-naive patients with advanced NSCLC harboring an EGFR mutation were
      enrolled. All patients underwent induction chemotherapy by sequentially
      alternating pemetrexed/cisplatin/bevacizumab and EGFR-TKIs followed by
      maintenance therapy with pemetrexed/bevacizumab and EGFR-TKIs. The primary
      outcome was the completion rate of the induction therapy. RESULTS: Eighteen
      eligible patients were enrolled between May 2011 and March 2016. The completion
      rate of induction therapy was 72.2% (13/18). Unfortunately, one patient developed
      grade 4 acute renal injury, but no other serious complications concerning this
      protocol were observed. Furthermore, diarrhea, rashes, and hematological adverse 
      effects were mild. CONCLUSION: The completion rate of induction therapy was
      promising. Alternating chemotherapy and EGFR-TKIs should be further investigated 
      regarding feasibility and efficacy.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Takemura, Yoshizumi
AU  - Takemura Y
AD  - Department of Pulmonary Medicine, Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
FAU - Chihara, Yusuke
AU  - Chihara Y
AD  - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine,
      Kyoto, Japan.
FAU - Morimoto, Yoshie
AU  - Morimoto Y
AD  - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine,
      Kyoto, Japan.
FAU - Tanimura, Keiko
AU  - Tanimura K
AD  - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine,
      Kyoto, Japan.
FAU - Imabayashi, Tatsuya
AU  - Imabayashi T
AD  - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine,
      Kyoto, Japan.
FAU - Seko, Yurie
AU  - Seko Y
AD  - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine,
      Kyoto, Japan.
FAU - Kaneko, Yoshiko
AU  - Kaneko Y
AD  - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine,
      Kyoto, Japan.
FAU - Date, Koji
AU  - Date K
AD  - Department of Pulmonary Medicine, Nantan General Hospital, Kyoto, Japan.
FAU - Ueda, Mikio
AU  - Ueda M
AD  - Department of Pulmonary Medicine, Nishijin Hospital, Kyoto, Japan.
FAU - Arimoto, Taichiro
AU  - Arimoto T
AD  - Kyoto Kojo Hokenkai Clinic, Kyoto, Japan.
FAU - Iwasaki, Yoshinobu
AU  - Iwasaki Y
AD  - Department of Pulmonary Medicine, Showa General Hospital, Tokyo, Japan.
FAU - Takayama, Koichi
AU  - Takayama K
AD  - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine,
      Kyoto, Japan [email protected]
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
RN  - Q20Q21Q62J (Cisplatin)
RN  - S65743JHBS (gefitinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse
      effects
MH  - Bevacizumab/administration & dosage/adverse effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/mortality/pathology
MH  - Cisplatin/administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - Erlotinib Hydrochloride/administration & dosage/adverse effects
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Induction Chemotherapy/adverse effects/methods
MH  - Lung Neoplasms/*drug therapy/genetics/mortality/pathology
MH  - Maintenance Chemotherapy/adverse effects/methods
MH  - Male
MH  - Middle Aged
MH  - Pemetrexed/administration & dosage/adverse effects
MH  - Protein Kinase Inhibitors/*administration & dosage/adverse effects
MH  - Quinazolines/administration & dosage/adverse effects
MH  - Receptor, Epidermal Growth Factor/antagonists & inhibitors/genetics
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *Alternating chemotherapy
OT  - *epidermal growth factor receptor tyrosine kinase inhibitor
OT  - *non-small cell lung cancer
OT  - *pemetrexed
EDAT- 2018/03/31 06:00
MHDA- 2018/04/13 06:00
CRDT- 2018/03/31 06:00
PHST- 2018/01/26 00:00 [received]
PHST- 2018/02/19 00:00 [revised]
PHST- 2018/02/20 00:00 [accepted]
PHST- 2018/03/31 06:00 [entrez]
PHST- 2018/03/31 06:00 [pubmed]
PHST- 2018/04/13 06:00 [medline]
AID - 38/4/2385 [pii]
AID - 10.21873/anticanres.12487 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Apr;38(4):2385-2390. doi: 10.21873/anticanres.12487.